All In Biotech

Drug Trial Radar · NCT05224401

Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in ESBL UTIs

Pivmecillinam With Amoxicillin/Clavulanic Acid for Step Down Oral Therapy in Febrile UTIs Caused by ESBL-producing Enterobacterales (PACUTI)

Last checked: Nov 20, 2026Latest source record: Aug 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 330 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

330

Planned (sponsor's estimate)

Start

May 29, 2023

Primary completion

Sep 1, 2027

Study completion Sep 1, 2027

Sponsor

Lead sponsor
Lund UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate if the combination of pivmecillinam and clavulanic acid (PAC) is non-inferior to ciprofloxacin, trimethoprim-sulfamethoxazole or ertapenem as step down oral therapy in patients with febrile UTI caused by extended spectrum beta-lactamase (ESBL) producing Enterobacterales (EPE).

Conditions

  • Urinary Tract Infections
  • Bacteremia
  • Antibiotic Resistant Infection

Interventions

  • Pivmecillinam and amoxicillin/clavulanic acidDrug

    1 tablet pivmecillinam 400 mg and 1 tablet Amoxicillin/clavulanic acid 875/125 mg, three times daily.

  • Standard treatment, ciprofloxacin, trimethoprim/sulfamethoxazole or ertapenem depending on susceptibilityDrug

    Ciprofloxacin 500 mg twice daily, trimethoprim/sulfamethoxazole 800 mg/160 mg twice daily or ertapenem 1 g once daily.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Clinical cureTime frame: Clinical cure 10 days (+/- 2 days)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Helsingborg hospital

    Helsingborg, Sweden · Recruiting

  • Kristianstad hospital

    Kristianstad, Sweden · Recruiting

  • Skåne University Hospital, Lund

    Lund, Sweden · Recruiting

  • Skåne University Hospital, Malmö

    Malmö, Sweden · Recruiting

  • Västmanland hospital Västerås

    Västerås, Sweden · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.